Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo controlled EVOLVE-1, EVOLVE-2 and REGAIN studies

被引：0
|
作者：
Aurora, Sheena K. [1 ]
Zhang, Qi [1 ]
Stauffer, Virginia L. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O18
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert
    NEUROLOGY, 2020, 94 (15)
  • [42] Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    Sun-Edelstein, Christina
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Barash, Steve
    Brandes, Jan Lewis
    NEUROLOGY, 2021, 96 (15)
  • [43] Evaluation of cardiovascular risks in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled studies
    Oakes, T. M.
    Kovacs, R.
    Rosen, N.
    Doty, E. G.
    Kemmer, P.
    Aurora, S. K.
    Camporeale, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 295 - 295
  • [44] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, H. C.
    Wang, S.
    Skljarevski, V
    Ahl, J.
    Millen, B.
    Aurora, S. K.
    Yang, J.
    HEADACHE, 2017, 57 (08): : 1336 - 1337
  • [45] A Phase 3 Placebo-Controlled Study of Galcanezumab in Patients with Chronic Migraine: Results from the 3-month Double-Blind Treatment Phase of the REGAIN Study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    CEPHALALGIA, 2017, 37 : 338 - 338
  • [46] A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study
    Detke, Holland C.
    Wang, Shufang
    Skljarevski, Vladimir
    Ahl, Jonna
    Millen, Brian A.
    Aurora, Sheena K.
    Yang, Jyun Yan
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [47] Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab
    Ayer, David W.
    Skljarevski, Vladimir
    Ford, Janet H.
    Nyhuis, Allen W.
    Lipton, Richard B.
    Aurora, Sheena K.
    HEADACHE, 2018, 58 (08): : 1225 - 1235
  • [48] Impact of Fremanezumab on Disability Severity in Patients With Episodic and Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    Nagy, Abraham J.
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Ashina, Messoud
    NEUROLOGY, 2021, 96 (15)
  • [49] IMPACT OF FREMANEZUMAB ON DISABILITY SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE: POOLED RESULTS OF 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDIES
    Nagy, Abraham J.
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Ashina, Messoud
    CEPHALALGIA, 2020, 40 : 93 - 94
  • [50] CHANGES IN PATIENT FUNCTIONING AND DISABILITY IN A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING GALCANEZUMAB FOR CHRONIC MIGRAINE PREVENTION (REGAIN)
    Ford, J. H.
    Detke, H. C.
    Ayer, D.
    Wang, S.
    Tockhorn-Heidenreich, A.
    Nichols, R. M.
    CEPHALALGIA, 2018, 38 : 55 - 55
12345